drugset
drugset / Trial / NCT05933447

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

NCT05933447 ↗

Phase 1 Completed 27 enrolled Altavant Sciences GmbH Altasciences Company Inc. · collab
RandomizedCrossoverDouble-blindTreatment

Summary

To evaluate whether Rodatristat Ethyl prolongs the QTc interval when orally administered to healthy volunteers.

Timeline

Start
2023-05-12
Primary completion
2023-07-28
Completion
2023-07-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Rodatristat Ethyl Small molecule 300 mg Oral
Subject Rodatristat Ethyl Small molecule 600 mg Oral
Subject Rodatristat Ethyl Small molecule 900 mg Oral

Indications

No indication recorded.